clinical trial · NCT07495930
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®
Shanghai Henlius Biotech·phase1·not yet recruiting·n = 24
Health Adult SubjectsHLX319EU-Phesgo
brief summary
The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.
started
Apr 30, 2026
primary completion
Jul 1, 2026
completion
Oct 10, 2026
last updated
Apr 1, 2026
official title
A Randomized, Double-blind, Single Subcutaneous Administration, Parallel Control Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo® in Chinese Healthy Male Subjects.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol